Clinical trials
EBV clinical trials
Below are recruiting ebv clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT07670468RecruitingPhase 1/Phase 2
T-cell therapy for resistant viral infections after transplant or cancer treatment
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
SeoulAges 19 years+ - NCT05447169Recruiting
Testing blood and DNA checks for nasopharyngeal cancer risk
This study tests an Epstein-Barr virus (EBV) blood antibody and an EBV DNA test to help screen people at higher risk for nasopharyngeal cancer. It may find signs earlier in certain families where cancer runs.
Guangzhou, GuangdongAges 30–62 - NCT04085900Recruiting
Screening test for nasopharyngeal cancer blood markers
This study screens people in certain cities to see whether signs in the blood related to a virus (EBV) can help find nasopharyngeal cancer earlier. It may help identify higher-risk people so they can be checked sooner.
Zhongshan, GuangdongAges 30–69 - NCT03258567RecruitingPhase 2
Nivolumab for EBV-related lymphomas and abnormal immune illnesses
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Bethesda, MarylandAges 12 years+ - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT02912897RecruitingPhase 1
EBV T-cell treatment for early multiple sclerosis-like symptoms
This early-phase study tests whether a patient’s own immune cells (made to target a common virus called EBV) are safe and practical for people who have their first episode that strongly suggests multiple sclerosis. If it works well, it could offer a new way to treat early disease—but the main goal now is safety and feasibility.
NantesAges 18–45 - NCT07369739RecruitingPhase 2/Phase 3
Combination therapy for chronic active Epstein-Barr virus disease
This trial tests two drugs, golidocitinib and selinexor, given together to treat chronic active Epstein-Barr virus disease (CAEBVD). The goal is to see if this combination can help control the disease better than current options.
BeijingAges 18–70 - NCT07348575Enrolling by invitationPhase 3
Decitabine plus R-CHOP for EBV-positive DLBCL
This trial tests whether adding a drug called decitabine to the standard chemo-immunotherapy R-CHOP can help people with a specific type of lymphoma (DLBCL that is positive for EBV) who have not been treated before. The goal is to see if the combination works better than R-CHOP alone.
Nanchang, JiangxiAges 18–75 - NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT07306156RecruitingPhase 1/Phase 2
GP350 CAR-T for Epstein-Barr virus related lymphoma
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Hefei, AnhuiAges 18–70 - NCT06702072Recruiting
Oxygen use after lung valve treatment
Researchers want to see if a bronchoscopic lung volume reduction procedure with Zephyr valves changes how much oxygen your body uses during simple tasks. You may be eligible if you are scheduled for this valve treatment and do not rely on constant oxygen for daily activities.
GroningenAges Any age - NCT07067268RecruitingPhase 2
Tislelizumab and capecitabine for nasopharyngeal cancer with remaining EBV DNA
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Shanghai, ChinaAges 18 years+ - NCT07019870Recruiting
Screening for early diagnosis of nose cancer
This trial offers free screening to find nose cancer (nasopharyngeal carcinoma or NPC) early, before symptoms start. It is for people with a family history of NPC who may be at higher risk.
SingaporeAges 35–60 - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT06682442Recruiting
Chemotherapy-guided radiation for EBV-related nasopharyngeal cancer
This trial tests whether the response to initial chemotherapy can guide the dose of radiation given to patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. The goal is to tailor treatment to reduce side effects while still being effective.
San Francisco, CaliforniaAges 18 years+ - NCT06689397Enrolling by invitation
Study of Epstein-Barr virus-related pink eye
This trial is studying a specific type of eye infection (pink eye) caused by the Epstein-Barr virus. It aims to better understand the condition and may help guide treatment for people with these symptoms.
LondonAges 16 years+ - NCT06672705RecruitingPhase 1
Epcoritamab for lymphoma that returns after an organ transplant
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
St Louis, MissouriAges 18 years+ - NCT04013802RecruitingPhase 1
Multivirus T-cell treatment for EBV, CMV, adenovirus, and BK after transplant
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
Houston, TexasAges Any age - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06321939Recruiting
Tracking EBV DNA in Blood for Nasopharyngeal Cancer
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
Changsha, HunanAges 18 years+ - NCT06203314Recruiting
Epstein-Barr virus and cancer risk study
This study looks at how Epstein-Barr virus (a common virus) may be linked to cancer risk. If you live in Zhongshan or Wuzhou City and are generally healthy, you may be able to join and help researchers learn more.
Zhongshan, GuangdongAges 30–69 - NCT06069830Recruiting
PET scan and EBV test guided treatment for nasal NK/T cell lymphoma
This trial uses PET scans and EBV DNA levels to personalize treatment for patients with early-stage nasal NK/T cell lymphoma. It aims to reduce side effects by adjusting therapy based on how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07685457Recruiting
Virus-specific T cells for stubborn viral infections after transplant
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
SeoulAges 1–25
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ebv?
- Yes. Clin2 currently lists 64 recruiting ebv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ebv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ebv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.